The revised IMWG criteria redefining myeloma and related disorders was published in 2014 in @TheLancetOncol — and is now the most cited paper in the field. thelancet.com/journals/lanon…
The next step for me is to classify myeloma into distinct entities based on the underlying primary cytogenetic type: a vision @myelomaMD and I outlined in The Multiple Myelomas. @NatRevClinOncolnature.com/articles/s4157…
I just attended one of the biggest cancer meetings in the world. #ASH22@ASH_hematology
For my followers here is a snapshot of the incredible progress happening with cancer treatment. It’s good. Thread.
1/ There is a revolution in cancer therapy that uses the power of our own immune system to fight cancer cells:
CAR-T cells
Bispecific antibodies
Both these approaches have already produced spectacular results in many cancers and we are just starting.
2/ CAR-T cells: take your own immune system cells out, engineer them to target a specific cancer, and then put them back in the body to go kill the cancer cells. A few CAR-T products have already been FDA approved. Many more to come. my.clevelandclinic.org/health/treatme…
Early transplant preferred. But for selected standard risk patients depending on preference, delayed is also OK. Maintenance varies by risk stratification.
3. First relapse. The approach depends on refractoriness to Len and CD38moAB. For CD38 Moab either Daratumumab or Isatuximab are OK. Depends on cost and availability. #ASH22
At #ASH22 my colleague @myelomaMD will present the initial results of the ASCENT trial, aka the 2nd Cure trial to test the hypothesis whether myeloma can be cured if highly active combination therapy is given early at the smoldering myeloma stage. ash.confex.com/ash/2022/webpr…
Updated results from the 1st Cure trial, GEM-CESAR led by @mvmateos is also being presented at #ASH22
These trials are part of a planned series of trials investigating whether the incurability of myeloma is related to the fact that we have traditionally started effective therapy only after the disease has spread and mutated to the point where it is no longer curable.
I was honored to lead this effort for the IMWG. A thread on the main changes.
1/
2/ The paradigm shifting change was including 3 biomarkers that were associated with 80% or greater probability of progression within 2 years as myeloma defining events on top of CRAB.
Here are my Top 5 #ASH22@ASH_hematology myeloma abstracts. #ASH22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology